Background: Long-term follow-up of population-based randomized, controlled trials (RCTs) has demonstrated that screening for abdominal aortic aneurysms (AAAs) measuring 3 cm or greater decreases AAA-related mortality rates in men aged 65 years or older.
A n abdominal aortic aneurysm (AAA) is a weakening in the wall of the infrarenal aorta that results in an anteroposterior diameter of 3 cm or greater (1) . Abdominal aortic aneurysms are often undiagnosed because a large proportion are asymptomatic until the development of rupture, which is generally acute and often fatal (59% to 83% of patients die before hospitalization) (2) . Significant risk factors for the development of AAA include advanced age (3), male sex (4), smoking (1, 5, 6) , and family history of AAAs (1, 7, 8) . Other potential risk factors include a history of other vascular aneurysms (9) , coronary artery disease (10) , cerebrovascular disease (9), atherosclerosis (10) , hypercholesterolemia (10) , and hypertension (1, 10) . Protective factors include black race, female sex, and diabetes mellitus (11) . Smoking is the most important modifiable risk factor for AAA development (12) (13) (14) and aneurysm growth (15). Older age, female sex, smoking, and higher blood pressure are associated with increased risk for rupture in patients with small (3.0 to 5.4 cm) AAAs (15).
Although several screening methods exist, ultrasonography is accepted as the standard screening imaging method for AAA because it has a high sensitivity (94% to 100%) and specificity (98% to 100%) (1, 2, 16 -19). Ultrasonography is noninvasive, can be conducted at a low cost, and does not involve radiation exposure. Computed tomography scans are highly sensitive and specific in detecting AAAs but are not recommended for first-line screening because of high cost and radiation exposure (1, 20) .
In 2005, the U.S. Preventive Services Task Force (USPSTF) found good evidence to recommend 1-time screening for AAA by ultrasonography in men aged 65 to 75 years who have ever smoked (B recommendation). The USPSTF concluded that the benefits of screening did not clearly outweigh the harms and did not make a general recommendation for or against screening for AAA in men aged 65 to 75 years who have never smoked (C recommendation). The USPSTF recommended against routine screening for AAA in women (D recommendation) (21) . This systematic review includes newly identified literature and all trials from the previous review that meet current inclusion criteria to provide updated evidence on the effectiveness of 1-time and repeated ultrasonography screening for AAAs (6) .
taskforce.org) (22) . This review addressed the following key questions: the effect of 1-time screening for AAAs of all sizes (Ն3.0 cm) and repeated screening for initially normal-sized aortas (Ͻ3.0 cm) on health outcomes and the harms related to 1-time and repeated screening for AAAs (Appendix Figure, available at www.annals.org). Of note, our detailed critique of treatment evidence for AAAs identified through screening that did not meet the currently accepted treatment threshold of 5 cm is presented in the full evidence report.
Data Sources and Searches
We searched MEDLINE, the Database of Abstracts of Reviews of Effects, and the Cochrane Central Register of Controlled Trials for relevant English-language studies published between January 2004 and January 2013. We searched for screening trials through September 2013 in MEDLINE. We supplemented searches with suggestions from experts and considered all articles included in the previous review for the USPSTF. We also reviewed reference lists of relevant systematic reviews and meta-analyses.
Study Selection
Two investigators independently reviewed abstracts and full-text articles for inclusion according to predetermined criteria. We resolved discrepancies through consensus with a third investigator. We considered randomized, controlled trials (RCTs) and large cohort studies (Ն1000 participants) of asymptomatic adult populations for key questions examining the effectiveness of 1-time and repeated screening. For the key question examining the harms of screening for AAAs, we considered RCTs and observational studies. Ultrasonography was the only screening method we considered. For all bodies of evidence, we excluded studies that we rated as poor-quality on the basis of the USPSTF quality rating standards (23) .
Data Extraction and Quality Assessment
One investigator extracted data, and a second investigator reviewed these data. Two investigators completed independent critical appraisals of all relevant studies by using the USPSTF's design-specific criteria (23), the National Institute for Health and Care Excellence method checklists (24), the Quality Assessment of Diagnostic Accuracy Studies (25) tool, and the Newcastle-Ottawa Scale (26) . According to the USPSTF criteria, a good-quality study met all prespecified standards. A fair-quality study did not meet (or it was unclear whether it met) at least 1 criterion, but it also had no known limitation that could invalidate its results. A poor-quality study had a single fatal flaw or several important limitations that would likely bias results.
Data Synthesis and Analysis
We qualitatively synthesized data for each key question by summarizing relevant details and results for each included study. Although we decided a priori to pool studies for all outcomes using DerSimonian-Laird randomeffects models, we report quantitative analyses only for allcause mortality. When we pooled AAA-related mortality and screening harms, the summary effects showed high statistical heterogeneity at the longest follow-up. Thus, we present forest plots with no pooled summaries. In addition, we did not pool studies examining the effectiveness of rescreening because of substantial differences in patient population, length of follow-up, and reported outcomes. For all pooled results using the DerSimonian-Laird randomeffects models, see the full evidence report (22) .
For all-cause mortality, we conducted planned randomeffects analyses using the DerSimonian-Laird method (27) . We conducted sensitivity analyses using a fixedeffects model as well as the profile likelihood method because there were only 3 trials and the DerSimonian-Laird method can underestimate uncertainty when the number of trials is small (27, 28) . The 2 methods resulted in identical effect estimates and CIs. We examined heterogeneity across trials with the I 2 statistic and chi-square test for heterogeneity.
Role of the Funding Source
This study was funded by the Agency for Healthcare Research and Quality (AHRQ) under a contract to support the work of the USPSTF. Members of the USPSTF and the AHRQ medical officer assisted in the development of the review's scope. Approval from AHRQ was required before the manuscript could be submitted for publication, but the authors are solely responsible for its content and the decision to submit it for publication.
RESULTS
We reviewed 2723 abstracts and 204 full-text articles and identified 4 trials addressing the benefits of 1-time screening, 10 studies on the effectiveness of rescreening, 7 studies addressing the harms of 1-time and repeated screening, 15 trials examining the benefits of treating small AAAs, and 15 studies on the harms associated with treating small AAAs (Figure 1) . The evidence related to the treatment of small AAAs is discussed in our full evidence report (22) , along with detailed study-level and summary results of the evidence related to AAA screening.
AAA Screening in Men
We identified 2 fair-quality and 2 good-quality population-based screening RCTs (137 214 participants) that assessed the efficacy of AAA screening in populationbased settings: MASS (Multicentre Aneurysm Screening Study) (29 -32); the Chichester, United Kingdom screening trial (33) (34) (35) (36) ; the Viborg County, Denmark screening trial (37) (38) (39) (40) (41) ; and the western Australian screening trial (42) ( Table 1 ). All trials used population registries or regional health directories to identify potential participants aged 64 or 65 years or older. The Chichester trial (33) was the only trial that included women (34) . No trial reported outcomes by demographic characteristics other than age and sex. Three of the 4 trials described adequate randomization (30, 33, 37) . Three had no trial exclusions, whereas MASS excluded patients who were identified as being too high-risk to be screened by their primary care physicians, were terminally ill, or had other serious health problems or previous AAA repair (30) . All trials randomly assigned participants to usual care or invitation for 1-time ultrasonography screening. Three specified postscreening ultrasonography surveillance protocols for AAAs measuring 3.0 cm or greater (30, 33, 39) , whereas the western Australian trial sent initial ultrasound results to primary care physicians for further management (42) .
All trials used intention-to-treat analysis. Adherence to screening varied from the lowest in the western Australian trial (62.5% of invited attended screening) to the greatest in MASS (80.2% adherence). Less than 1% of the control group crossed over in any trial to receive elective surgery, even at the longest follow-up of 13 to 15 years.
The primary trial outcome was AAA-specific mortality (defined as all AAA deaths plus all deaths within 30 days of AAA surgical repair). Trials also reported AAA rupture and all-cause mortality rates. Deaths and their causes were ascertained from death certificates in all studies, and 3 used a blinded adjudication panel to assign causes of death using autopsy data and hospital records.
Abdominal aortic aneurysm prevalence varied from 4.0% to 7.6% ( Table 1) . Most (70% to 82%) screendetected AAAs were small, measuring less than 4.0 to 4.5 cm. Abdominal aortic aneurysms measuring 5.5 cm or greater were detected in only 0.4% to 0.6% of the screened groups. The good-quality MASS and Viborg trials showed statistically significant reductions in AAA-related mortality rates with screening at all time points beginning at 3 years and persisting up to 15 years (30, 37) ( Table 2 ). The Chichester and western Australian trials showed a tendency toward reductions in AAA-related mortality rates with screening that was not statistically significant (33, 42 ). An invitation to AAA screening was not associated with a consistent statistically significant all-cause mortality benefit in any of the individual trials or in the pooled random-effects analysis at any time point up to 15 years ( Table 2) . Sensitivity analyses that were done using a fixedeffects model yielded statistically significant findings (hazard ratio, 0.97 [95% CI, 0.96 -0.99]), and sensitivity analyses at the 13-to 15-year time point using the profile likelihood estimation method yielded identical results to the random effects model (risk ratio, 0. An invitation for screening was associated with lower AAA rupture rates than no invitation at all time points in the MASS and Viborg trials. In addition, a nonstatistically significant tendency toward a reduction in ruptures was seen in the Chichester trial at 13 years, and no difference was reported in the western Australian trial at 3.6 years (Figure 2) . Two of the 4 trials (Viborg and MASS) showed fewer emergency surgeries in the invited group up to 10 to 13 years. Chichester showed a nonsignificant tendency toward fewer emergency surgeries in the invited group up to 15 years, and the western Australian trial showed a nonstatistically significant increase in emergency surgery in the invited group at 3.6 years.
Screening for AAA in Women
Only the Chichester study recruited female participants, and these women were aged 65 to 80 years (9342 women [59% of participants]) (34) . Abdominal aortic aneurysm prevalence in women was 6 times lower than in men (1.3% vs. 7.6%). Most (30 of 40) AAAs were small (3.0 to 3.9 cm), and AAA-specific mortality rates were low in both groups (Ͻ0.2%; no statistical analysis). All-cause mortality rates at 5 years and rupture rates at 5 and 10 years were similar in the invited and control groups. Because of the low prevalence of AAA in women, the trial was underpowered to detect differences in health outcomes. A separate analysis that considered the entire unscreened population in the Chichester trial showed that more than half of the AAA deaths in men occurred before age 80 years, whereas most (70%) AAA deaths in women occurred at age 80 years or older (34) .
Screening for AAA in High-Risk Populations
In addition to male sex, strong risk factors for AAA include age, smoking, and family history (12) (13) (14) . The oldest participants in the 4 major screening trials ranged from age 73 to 80 years. Two trials reported no differences in AAA-related mortality outcomes when stratified by age (40, 42) . In a simulation analysis after randomization from the Viborg trial, selective high-risk screening (only patients with chronic obstructive pulmonary disease or other cardiovascular conditions) would have prevented nearly half We identified 1 good-quality and 6 fair-quality prospective cohort studies that examined various rescreening protocols (43) (44) (45) (46) (47) (48) (49) . Studies showed that AAA-related death over 5 to 12 years was rare (Ͻ3%) among patients with normal aortas (Ͻ3.0 cm) on the initial scan (43-49) (data not shown). Few of those with aortas measuring less than 3.0 cm developed any AAA over the following 5 to 12 years, which was particularly true for aortas less than 2.5 cm. Although some aortas (19% to 88%) with initial diameters of 2.5 to 2.9 cm progressed to a small AAA (diameter Ͼ3.0 cm) after 5 to 6 years, very few increased to greater than 5.0 cm (0.0% to 2.4%) at 5 years (48 -50) and 15% had progressed to greater than 5.4 cm at 10 years (51). We identified 1 fair-quality meta-analysis of individual-patient data that confirmed that AAA rupture was rare (Ͻ1%) in patients with subaneurysmal aortic dilatation (2.5 to 2.9 cm) over a mean of 13.2 years (52). Overall, this rescreening literature was limited by studies with small numbers of participants with normal aortas, no matched control participants, and primary outcomes of expansion rates rather than health outcomes (52) .
One good-quality cohort study (2622 participants) that analyzed AAA detection and AAA-related mortality rates with rescreening at 4 years using multilogistic regression models showed that current smoking, coronary artery disease, and any atherosclerosis were associated with AAA detection at rescreening (44) . In addition, no AAA ruptures or AAA deaths were identified during 4 years of follow-up. One fair-quality cohort study examined the association of age with aortic size less than 3.0 cm at initial scan for development of an AAA and found no association between age group and subsequent AAA-related death (47) . This cohort study (47) was an analysis of a single center that was included in the aforementioned goodquality cohort study (44) . These conclusions about the yield of rescreening in subgroups are limited by very few nonwhite or female participants and by using only national death certificate information for mortality data.
Harms Associated With Screening
All 4 large population-based screening RCTs reported results on operative death and number of AAA surgeries (30, 33, 37, 42) (Figure 2) . The risk for any AAA-related operation in the invited group was approximately double that of the noninvited group at 3 to 5 years in all trials (hazard ratio of 2.4 in MASS and Viborg; hazard ratio of 1.70 and 1.87 in Chichester and western Australian), which was driven by more elective surgeries in the invited group in all trials at all time points. The Chichester trial and MASS showed some attenuation over time: By 13 to 15 years, there were 50% more AAA-related operations in the invited group compared with the control group. An unchanged risk over time was reported in Viborg. Thirtyday postoperative mortality rates after elective surgery in the only trial reporting this outcome at various time points (MASS) were similar between groups but were significantly reduced after emergency surgery in the screened group for all periods up to 10-year follow-up compared with the control group. We identified 5 small observational studies (3 cohort and 2 cross-sectional) that reported conflicting results of AAA screening's influence on quality of life (QOL) and anxiety or depression measures (data not shown, single study excluded for quality [53] ) (30, 54 -57) . One study reported short-term decreases in QOL at 12 months in those who screened positive for AAA (55) . Four studies showed no clinically important decrease in QOL measures in those who screened positive for AAA compared with unscreened control participants (30, 54, 56, 57 ). Of note, no trial used AAA-specific QOL instruments.
DISCUSSION
Our systematic review of 4 population-based screening trials (30, 33, 37, 42) found convincing direct evidence that screening men aged 65 years or older decreased AAArelated mortality rates by approximately 50% over 13 to 15 years (58 -60) . Abdominal aortic aneurysm-related mortality benefits occurred relatively early (by roughly 4 years) and were maintained for at least another decade. In contrast to the previous review for the USPSTF (6), we do not present pooled estimates of effect on AAA-related mortality rates because of high statistical heterogeneity, although they are available in the full report (22) . Subsequent to this previous review (6) , some work also suggested that certain random-effects models (such as DerSimonian-Laird) may significantly underestimate statistical heterogeneity (27) and that, particularly when there are small study numbers, alternate statistical methods may provide more appropriate variance estimates (27, 28, 61, 62) . Therefore, for the presentation of AAA-related mortality benefits, we emphasized the findings from the largest good-quality study (MASS). In previous years, the estimates of treatment benefit on AAA-related mortality in MASS were similar to the overall RR ϭ risk ratio.
Review Ultrasonography Screening for Abdominal Aortic Aneurysms pooled effects used for screening recommendations. This is not surprising given its disproportionately large sample size. Moreover, relying on MASS alone to estimate AAArelated mortality benefit at 13 to 15 years provides data that are essentially consistent with previous reviews done for the USPSTF that used a slightly different method. Because of the lack of apparent heterogeneity, we pooled the longer-term all-cause mortality data using our prespecified (a priori) random-effects model, which was based on the DerSimonian-Laird model. We repeated the analysis using an alternative statistical approach, the profile likelihood method. Both methods produced the same pooled estimate of a nonstatistically significant reduction in all-cause mortality rates, which stands in contrast to authors' conclusions from a fixed-effects meta-analysis (63) . Deaths due to AAA represented less than 3% of all deaths. We do not believe that the available data firmly support a reduction in all-cause mortality rates with AAA screening. It is important to note that although age is the strongest risk factor for AAA (12, 13) , competing causes of death and limited surgical candidacy due to comorbid conditions diminish the effectiveness of AAA screening.
Although we found minimal direct evidence addressing subgroups in our systematic review, determining the most effective and efficient approaches to population-based AAA screening remains an important issue. In response to the 2005 USPSTF recommendation for a selective screening approach targeting men aged 65 to 75 years who have ever smoked, concerns have been voiced about missed opportunities to prevent AAA rupture, particularly in women, younger nonsmoking males, and those with a family history of AAA. Critics note the substantial rupture rates and AAA-related deaths that occur in women (at least 33% of hospitalizations for ruptured AAA and 41% of AAA-related deaths), and nonsmokers account for approximately 22% of AAA-related deaths (64 -67) . A different high-risk approach using a validated multifactorial risk calculator that considers family history, cardiovascular disease, race, body mass index, and other factors could identify a group with increased prevalence of AAA and thereby could more effectively identify AAAs and be equally efficient. However, many higher-risk persons have known comorbid conditions that could affect either eligibility or complications associated with surgical treatment and could compromise the ability to attend surveillance.
As an example of a high-risk approach, screening programs targeting women who currently smoke could increase screening yield, but one must weigh these possible benefits against the greater surgical complication rate and older age at time of rupture compared with men (34, 67) . Some current screening strategies have targeted persons with family history who have a reported AAA prevalence of 4% to 11%, particularly siblings of patients with AAA (68 -70); however, no direct evidence exists for screening benefits in those with a family history of AAA. Recently, investigators have developed and internally validated a novel scoring tool to predict prevalent AAA using demographic and medical history data from 3.1 million persons who volunteered for community-based ultrasonography screening. Although promising, this risk scoring must be validated in the general population (12) .
Recent epidemiologic evidence from population-based screening programs in Europe and New Zealand demonstrates a substantial decrease in AAA prevalence in men aged 65 years or older over the past 2 decades, with current AAA prevalence reported at 1.5% to 1.7% (51, (71) (72) (73) . The United States lacks similar prevalence reporting, probably because of low screening uptake, which makes it difficult to estimate true AAA prevalence (74) . Decreasing smoking rates could largely account for this decline abroad (75, 76) , although decreasing atherosclerotic disease due to aggressive management of hypertension and hyperlipidemia probably also contributes to this decline (72, 76) . One recent study suggests that the risk for AAA in persons who have ever smoked may remain high with a shift toward smaller aneurysms, even if the overall prevalence of AAA were declining in the United States as it is in other countries (77) . This decrease in prevalence must be carefully considered when estimating the yield from mass versus targeted screening approaches and certainly favors a more targeted approach (that is, persons who have ever smoked). No single risk factor other than age, sex, or smoking history is as strong of a predictor of AAA, which makes developing a multiple risk factor approach appealing once a validated risk score is available.
Limitations of this review include only evaluating English-language literature and RCTs or large cohort studies and a requirement that studies meet the USPSTF's fairor good-quality criteria (23) . In addition, directly applying the benefits realized in the trials with populations with access to universal health care to the U.S. population may be optimistic. Because this review was conducted to update a previous USPSTF review (6), some issues, such as risk assessment, incidental AAA detection on computed tomography screening for other purposes, and possible sex differences in the risk for rupture at a specific aortic diameter, were not systematically reviewed. (2) ; these data are shown in Table 2 of the manuscript and seem to contradict our statement. Dr. Lederle also questioned whether pooled results for all-cause mortality with upper CIs of 1.00 may in some cases be statistically significant if carried to 3 decimal places. We would like to walk Annals readers through these issues and our series of analyses to clarify what may appear to be discrepancies in our results and conclusions.
The overarching issues involved with seemingly contradictory interpretations of the evidence reflect the complexity of analysis for all-cause mortality, whereby the overall effect on this outcome is very small, and statistical significance of pooled results is highly dependent on analytic approaches and decisions. Further, readers should be aware that different risk measures (i.e., HR vs. relative risk [RR]) may affect results. Primarily due to study-level reporting, we focused our synthesis on RR measures to maximize data availability across trials.
To harmonize reported outcome measures across trials, we recalculated study-level data to produce an RR for the 13 year timepoint in MASS (RR, 0.985 [CI 0.949 to 0.998]). We rounded this RR point estimate and 95% CI to 2 digits beyond the decimal, as is our convention. As a result, the 95% CI included 1.00 and was not considered statistically significant, in contrast to the study-reported HR. Our use of no more than 2 significant digits is long-standing and we believe appropriate, given that few studies report effect size measures beyond 2 digits, and study-level data are our primary data source. Although we stand by our rounding approach, we acknowledge that different approaches could lead people to somewhat different conclusions, particularly if one adheres to conventional indicators of statistical significance as their primary focus.
In summarizing data across trials, we focused on 2 different time points commonly reported by trials to indicate short-and longer-term clinical impact: the initial 3-to 5-year end point available from all 4 trials (3-6), and the 13-to 15-year time frame available from only 3 of the 4 trials (2, 7, 8) . Like others in the field, we pooled the longest available follow-up for all 4 included trials; this included the 3.6-year West Australian trial (6) . In our original analysis for the U.S. Preventive Services Task Force, we presented pooled results using a random-effects model with the DerSimonianLaird estimation method, with a sensitivity analysis examining a fixed-effects model, to provide comparisons to the work of previous reviewers in this area. Due to emerging consensus that this model can underestimate the 95% CI when a small number of trials are combined (9), we expanded our meta-analytic approach when developing our Annals manuscript. We also shifted our primary interpretation to emphasize the qualitative synthesis of the data, and to emphasize the more conservative profile likelihood estimation method for any pooled results.
As shown in the Table below, the choice of statistical model as well as rounding approach makes subtle differences in the final interpretation of long-term mortality results as "statistically significant" or not. The DerSimonian-Laird random-effects models for all-cause mortality at either 13 to 15 years or longest follow-up do not cross 1.00 at the upper 95% CI bound (RR, 0.986 [CI, 0.972 to 0.999]); however, after rounding to 2 significant digits we concluded a lack of statistical significance at this longest time point. When the profile likelihood random effects model is used, point estimates are quite similar, but the upper bound of the 95% CI crosses 1.00, regardless of rounding. Since we agreed that this approach was most appropriate, we emphasized it as our "bottom line," best estimate of a pooled result for this outcome.
Although details of the analytic approaches can be important to appreciate, we believe that there are other, perhaps more important, considerations when interpreting whether AAA screening is associated with an effect on all-cause mortality. These include the consistency of findings (across analytic approaches), as well as the size and clinical significance of any effect. We believe that these 2 perspectives suggest that any effect of AAA screening on all-cause mortality is slight, if present, and depends on the analytic approach taken and the time point considered. Any uncertainty is offset by a clearly beneficial effect on AAA-related mortality, which has been sufficient for evidencebased policy makers to recommend this screening service (10) .
To avoid any confusion, we appreciate the opportunity to issue an erratum for Table 2 , in order to clarify the source of the data in that table as representing those reported by the trials' authors. The title of Table 2 has been changed to the following: "All-Cause and AAA-Related Mortality Data for 1-Time Screening Trials at the Initial and Longest Follow-up as Reported in the Trials."
We have also amended our text reflecting the summary findings to clarify our results. On page 324, the word "consistent" has been added to the first sentence of the first full paragraph. The sentence now reads as follows: "An invitation to AAA screening was not associated with a consistent statistically significant all-cause mortality
